EcoDrugPlus

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSDCDG00000002795
Gene Symbol: AGTR1
3 Cross references
149 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSDCDG00000026162
Gene Symbol: AGTR1
3 Cross references
203 Possible Orthologues:

Angiotensin Ii Receptor Type 2

Ensembl ID : ENSDCDG00000035066
Gene Symbol: AGTR2
3 Cross references
171 Possible Orthologues:

Apelin Receptor B-Like

Ensembl ID : ENSDCDG00000029069
Gene Symbol: LOC114766131
3 Cross references
172 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSDCDG00000028610
Gene Symbol: APEX1
3 Cross references
214 Possible Orthologues:

Arachidonate 12-Lipoxygenase, 12s-Type-Like

Ensembl ID : ENSDCDG00000003674
Gene Symbol: LOC114786337
3 Cross references
200 Possible Orthologues:

Arachidonate 5-Lipoxygenase

Ensembl ID : ENSDCDG00000004858
Gene Symbol: ALOX5
3 Cross references
213 Possible Orthologues:

Arachidonate 5-Lipoxygenase Activating Protein

Ensembl ID : ENSDCDG00000034009
Gene Symbol: ALOX5AP
3 Cross references
201 Possible Orthologues:

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSDCDG00000032619
Gene Symbol: AVPR1A
3 Cross references
203 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSDCDG00000032179
Gene Symbol: AVPR2
3 Cross references
197 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSDCDG00000005367
Gene Symbol: AVPR2
3 Cross references
197 Possible Orthologues:

Aromatase-Like

Ensembl ID : ENSDCDG00000035826
Gene Symbol: LOC114766358
3 Cross references
255 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).